Racura Oncology Ltd (ASX:RAC)

Market Cap	505.17M
Revenue (ttm)	6.04M
Net Income (ttm)	-4.79M
Shares Out	179.14M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	56,413
Average Volume	164,977
Open	2.850
Previous Close	2.790
Day's Range	2.750 - 2.930
52-Week Range	0.920 - 4.900
Beta	1.10
RSI	49.26
Earnings Date	Feb 24, 2026

About Racura Oncology

Racura Oncology Ltd, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments in Australia. The company’s lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RAC

Financial Performance

In 2025, Racura Oncology's revenue was 6.04 million, an increase of 24.96% compared to the previous year's 4.84 million. Losses were -4.79 million, -65.36% less than in 2024.